Alnylam: 3Q Earnings Snapshot

November 7, 2018

CAMBRIDGE, Mass. (AP) _ Alnylam Pharmaceuticals Inc. (ALNY) on Wednesday reported a loss of $245.3 million in its third quarter.

The Cambridge, Massachusetts-based company said it had a loss of $2.43 per share. Losses, adjusted for stock option expense, came to $1.56 per share.

The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of $1.73 per share.

The RNA interference drug developer posted revenue of $2.1 million in the period, falling short of Street forecasts. Five analysts surveyed by Zacks expected $19.4 million.

Alnylam shares have decreased 32 percent since the beginning of the year. The stock has decreased 34 percent in the last 12 months.


This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ALNY at https://www.zacks.com/ap/ALNY

Update hourly